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Our aim was to determine Trichomonas vaginalis prevalence using the Aptima Trichomonas vaginalis assay (ATV; Gen-Probe)
and the prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae coinfections in U.S. women undergoing screening for
C. trachomatis/N. gonorrhoeae. Discarded urogenital samples from 7,593 women (18 to 89 years old) undergoing C. trachoma-
tis/N. gonorrhoeae screening using the Aptima Combo 2 assay (Gen-Probe) in various clinical settings were tested with ATV.
Overall, T. vaginalis, C. trachomatis, and N. gonorrhoeae prevalences were 8.7%, 6.7%, and 1.7%, respectively. T. vaginalis was
more prevalent than C. trachomatis or N. gonorrhoeae in all age groups except the 18- to 19-year-old group. The highest T. vagi-
nalis prevalence was in women >40 years old (>11%), while the highest C. trachomatis prevalence (9.2%) and N. gonorrhoeae
prevalence (2.2%) were in women <30 years old. Coinfection prevalences were 1.3% for C. trachomatis/T. vaginalis, 0.61% for
C. trachomatis/N. gonorrhoeae and N. gonorrhoeae/T. vaginalis, and 0.24% for C. trachomatis/N. gonorrhoeae/T. vaginalis and
highest in women <30 years old. T. vaginalis prevalence differed by race/ethnicity, with the highest prevalence in black women
(20.2%). T. vaginalis prevalence ranged from 5.4% in family planning clinics to 22.3% in jails. Multivariate analysis determined
that ages of >40 years, black race, and patient locations were significantly associated with T. vaginalis infection. T. vaginalis is
the most common sexually transmitted infection (STI) in women of >40 years, while C. trachomatis and N. gonorrhoeae preva-
lence is lowest in that age group. Higher T. vaginalis prevalence in women of >40 years is probably attributed to the reason for
testing, i.e., symptomatic status versus routine screening in younger women. Coinfections were relatively low. High T. vaginalis
prevalence in all age groups suggests that women screened for C. trachomatis/N. gonorrhoeae, whether asymptomatic or symp-
tomatic, should be screened for T. vaginalis.
Trichomoniasis, caused by the protozoan Trichomonas vagina-lis, is a common sexually transmitted infection (STI) affecting
men and women, with an estimated 7.4 million cases annually in
the United States (2, 6, 35). Approximately 50 to 60% of T. vagi-
nalis infections in women are asymptomatic (1). Available effec-
tive treatment makes T. vaginalis one of the most curable STIs
(35). Untreated T. vaginalis infections may result in long-term
sequelae, such as pelvic inflammatory disease, preterm births, or
low-birth-weight infants (7, 8). Moreover, T. vaginalis infection
has been shown to increase the risk of HIV sexual transmission
(20, 22, 31). Thus, detection of T. vaginalis is key for treatment,
reducing transmission, and preventing associated negative health
outcomes.
Currently, the gold standard for detection of T. vaginalis infec-
tion in women is culture of vaginal specimens. However, culture is
only moderately sensitive (75%) compared to nucleic acid am-
plification tests (NAATs), is costly, and takes 3 to 7 days to provide
results, thus making it unsuitable for routine clinical use (18, 25).
More-rapid techniques include microscopy (“wet mount”) of
vaginal fluid, the most commonly used test in the clinic, and an-
tigen detection (OSOM Trichomonas rapid test; Genzyme Diag-
nostics). However, sensitivity is low (50%) for microscopy and
only moderate (82%) for antigen tests (18, 25). These tests also
show poorer sensitivity in asymptomatic populations. Further-
more, by microscopy, it is difficult to differentiate T. vaginalis
from Pentatrichomonas hominis, a nonpathogenic gastrointestinal
commensal flagellate that can contaminate samples during collec-
tion. Another diagnostic option is the Affirm VP III DNA probe
test (Becton, Dickinson, San Jose, CA), which has moderate sen-
sitivity (64 to 80%) compared to wet mount and/or culture (3, 4).
PCR has moderately high sensitivity for T. vaginalis detection in
vaginal fluids (80% to 95%), but there is no U.S. Food and Drug
Administration (FDA)-approved PCR test for diagnosis of T.
vaginalis infection (14, 21, 25, 26, 34). The only FDA-cleared
NAAT for T. vaginalis is the Aptima Trichomonas vaginalis assay
(ATV; Gen-Probe Inc., San Diego, CA). Sample types include
urine, clinician-collected vaginal swabs (CVS), endocervical
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swabs (ES), and PreservCyt solution (Hologic Incorporated, Bed-
ford, MA) for liquid-based cytology (PCyt). A multicenter study
that determined ATV performance for FDA clearance demon-
strated that assay sensitivity ranged from 95.2% for urine to 100%
for CVS, ES, and PCyt samples (28). ATV was highly specific for T.
vaginalis (98.9%) (28). Additional U.S. studies demonstrated
that ATV has the highest sensitivity (95%) in vaginal fluid of the
available assays, including PCR, and has similarly high sensitivity
in other sample types (urine, ES, and PCyt) (3, 13, 16, 18, 25).
Andrea and Chapin demonstrated that the sensitivity of Affirm
was only 64% in a comparison with ATV (3).
The 2001 to 2004 National Health and Nutrition Examination
Surveys (NHANES) used PCR testing to determine the first na-
tional T. vaginalis infection prevalence (3.2%) in American
women 14 to 49 years old (1, 29). T. vaginalis infection was more
prevalent than Chlamydia trachomatis (2.2%) and Neisseria gon-
orrhoeae (0.24%) infections combined among women 14 to 39
years old (9). The National Longitudinal Study of Adolescent
Health, a prospective cohort study, used PCR testing and deter-
mined that the estimated T. vaginalis prevalence in young women
was 2.8% (23). Using 1,525 home-collected mailed vaginal swabs
and ATV, a recent report detected a T. vaginalis prevalence of 10%
(11). The 7.4 million incident T. vaginalis infections per year
makes T. vaginalis the most prevalent nonviral and treatable STI in
the United States (2, 33). Despite high prevalence, T. vaginalis
infections are currently not required to be reported to the U.S.
Centers for Disease Control and Prevention (CDC; Atlanta, GA).
The goal of this study was to determine T. vaginalis prevalence
by using the highly sensitive ATV assay in a large sample of women
aged 18 or older that were undergoing C. trachomatis/N. gonor-
rhoeae screening in a wide geographical area and by comparing T.
vaginalis prevalence to C. trachomatis and N. gonorrhoeae preva-
lence in the same samples.
(This work has been presented in part as an oral presentation at
the International Society for Sexually Transmitted Disease Re-
search [ISSTDR] Meeting, Quebec, Canada, July 2011.)
MATERIALS AND METHODS
Overall study design. Discarded, deidentified clinical specimens, col-
lected July through November 2010 from women for C. trachomatis/N.
gonorrhoeae testing with the Aptima Combo 2 assay (AC2; Gen-Probe
Inc., San Diego, CA) on the Tigris DTS instrumentation system (Tigris;
Gen-Probe) were used. AC2 is a NAAT that utilizes target capture speci-
men processing, transcription-mediated amplification (TMA), chemilu-
minescent probe hybridization, and the automated Tigris system to detect
C. trachomatis and N. gonorrhoeae ribosomal RNAs (rRNAs) in urogenital
samples. Samples from each participating laboratory were tested with the
research-use-only ATV kit on the Tigris system. Each laboratory reported
AC2 and ATV results and available deidentified demographic data to a
centralized database. Prevalence for T. vaginalis, C. trachomatis, and N.
gonorrhoeae and coinfection rates were determined.
Study population and sites. The study population included women
18 to 89 years old from 21 states who were with or without symptoms of
STIs. Due to the use of discarded, deidentified samples, information on
symptoms, sexual history, or STI history was not available. Therefore,
based on current CDC C. trachomatis/N. gonorrhoeae screening recom-
mendations (5, 35), samples collected from younger patients (26 years)
were probably more heavily weighted for routine screening (asymptom-
atic) than samples collected from older women which were probably more
associated with clinical symptoms. Collection sites included patients
treated in a hospital setting (emergency departments [ED] or hospital-
ized), obstetric/gynecologic (OB/GYN) practices, family planning clinics,
family practices, sexually transmitted disease (STD) clinics, or other clin-
ics performing tests for STIs. Eighteen laboratories throughout the United
States using AC2 participated. Ethical approval was obtained at each site
in accordance with institutional review board policies to release deidenti-
fied results and demographic information to Gen-Probe.
Clinical specimens. A total of 7,593 specimens, including self- or phy-
sician-collected vaginal swabs (CVS; n  791), ES (n  3,912), urine (n 
1,945), and ES specimens collected in PCyt (PCyt; n  940), were ob-
tained and tested for C. trachomatis/N. gonorrhoeae and T. vaginalis. Only
one specimen per patient, independent of specimen type, was tested. All
specimens were placed into the appropriate Aptima transport tubes be-
fore being shipped to the testing sites. CVS and ES specimens were added
directly into transport buffer tubes upon collection. Urine samples were
aliquoted at the collection site into Aptima urine specimen transport
tubes, and for PCyt samples, a 1-ml portion was transferred into a speci-
men transfer kit. Each site collected a minimum of 350 patient specimens.
Specimens were stored at 2 to 30°C and tested with ATV within 30 days of
collection or up to 60 days after collection if using ES or CVS. This is the
current time frame for testing C. trachomatis/N. gonorrhoeae from these
sample types for the Aptima Combo 2 assay. In-house data (Gen-Probe,
Inc.) have shown no loss of or decrease in ability to detect the T. vaginalis
target for the sample types listed under the conditions described for col-
lection and storage that are currently published in the package insert for
the Aptima T. vaginalis product.
ATV assay and sample testing. ATV is a NAAT that utilizes the same
technology and instrumentation as AC2 to detect T. vaginalis rRNA in
urogenital samples. Consecutive female samples meeting study entry cri-
teria were tested in accordance with ATV instructions on the Tigris in-
strument.
Data collection and statistical analysis. ATV results were transmitted
electronically to a central database. Associated C. trachomatis/N. gonor-
rhoeae results and deidentified demographic data (age, sex, race, clinic
type, and location [identified by the first 3 digits of the zip code]) were
entered into an electronic report form and sent for statistical analysis
performed primarily with PC SAS version 9.2 or higher (Cary, NC). For
categorical variables, summary statistics included the number of subjects
and percentage for each category. For continuous variables, summary
statistics included the number of observations and the mean, standard
deviation, median, minimum, and maximum values. Age-adjusted odds
ratios (ORs) were calculated via a multivariable logistic regression model
controlling for age in categories (20, 20 to 29, 30 to 39, and 40 years),
whereas multivariable ORs further controlled for collection site, race, and
geographical regions determined as Northeast (Delaware, Maryland,
Rhode Island, Connecticut, New Jersey, New York, Pennsylvania), South-
east (Louisiana, Florida, Georgia, Kansas, Kentucky, Tennessee, Virginia),
Southwest (California, Texas, New Mexico, Arizona, Colorado, Nevada,
Utah), and Midwest (Indiana, Michigan, Minnesota, Ohio, Illinois, Mis-
souri, Wisconsin). No patient specimens were collected from the North-
west region.
RESULTS
Overall prevalence of T. vaginalis, C. trachomatis, and N. gon-
orrhoeae infections. Overall prevalences of T. vaginalis, C. tracho-
matis, and N. gonorrhoeae infections were 8.7%, 6.7%, and 1.7%,
respectively (Table 1). Rates of coinfection were low (1.3%):
1.3% of subjects were coinfected with T. vaginalis and C. tracho-
matis, 0.61% were coinfected with T. vaginalis and N. gonorrhoeae,
0.61% were coinfected with C. trachomatis and N. gonorrhoeae,
and 0.24% of subjects had a triple coinfection (T. vaginalis, C.
trachomatis, and N. gonorrhoeae).
Prevalence of T. vaginalis, C. trachomatis, and N. gonor-
rhoeae infections by age. Of the three STIs surveyed, T. vaginalis
was the most prevalent in all age groups except the 18- to 19-year-
old group, for which C. trachomatis was the most prevalent (C.
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trachomatis, 14.4%; T. vaginalis, 8.5%; N. gonorrhoeae, 3.3%) (Ta-
ble 1 and Fig. 1). T. vaginalis prevalence was lowest in women 40
years old (range, 7.9% to 8.5%) and highest in women 40 years
old (11.3% in women 40 to 49 years old, 13.0% in women 50
years old). In contrast, C. trachomatis and N. gonorrhoeae preva-
lence was lowest in women 40 years old (2%) and highest in
women 30 years old (ranges, 8.0% to 14.4% for C. trachomatis
and 2.0% to 3.3% for N. gonorrhoeae). Double and triple coinfec-
tions were more common in women 30 years old than in women
30 years old (Table 1). Univariate and multivariate analyses (Ta-
ble 2) revealed a significant association between T. vaginalis infec-
tions and women aged 40 years.
Prevalence of T. vaginalis, C. trachomatis, and N. gonor-
rhoeae infections by race. STI prevalence varied greatly by race/
ethnicity. For racial groups with 100 subjects, T. vaginalis prev-
alence was highest for blacks (20.2%), followed by whites (5.7%)
and Hispanics/Latinos (5.0%) (Table 1 and Fig. 2). C. trachomatis
prevalence was highest for blacks (12.1%), followed by Hispanics/
Latinos (5.9%) and whites (5.7%) (Table 1). N. gonorrhoeae prev-
alence was highest for blacks (4.0%), followed by whites (1.6%)
and Hispanics/Latinos (0.7%) (Table 1). Blacks had relatively
higher rates of coinfection (T. vaginalis and C. trachomatis, 3.6%;
C. trachomatis and N. gonorrhoeae, 1.7%; T. vaginalis and N. gon-
orrhoeae, 1.7%) than other ethnicities (1%). Included in the
unknown/other category were subsets of ethnic groups, including
American Indians/Alaskan Natives (10.5%) and Native Hawai-
ians/Pacific Islanders (7.1%), with high T. vaginalis prevalence. T.
vaginalis, C. trachomatis, and N. gonorrhoeae prevalence rates in
the subset of Asian women were 3.8%, 9.9%, and 2.3%, respec-
tively. Univariate and multivariate analyses (Table 2) revealed a
significant association between T. vaginalis, C. trachomatis, and N.
gonorrhoeae infections and black women.
Prevalence of T. vaginalis, C. trachomatis, and N. gonor-
rhoeae infections by testing site and geographical location. T.
vaginalis prevalence varied greatly by sample collection site
(Table 1 and Fig. 3) and geographical location (Fig. 4). T. vagi-
nalis prevalence was highest among hospital-associated pa-
tients (16.6%) and jail inmates/STD clinic patients (16.4%),
followed by OB/GYN practices (7.3%) and family practice/in-
ternal medicine practices (6.1%), and lowest in family plan-
ning centers (5.4%). C. trachomatis prevalence was highest
among jail inmates/STD clinic patients (10.5%) and family
planning centers (10.4%), followed by family practice/internal
medicine practices (7.8%) and ED (7.3%), and lowest in OB/
GYN practices (4.4%). N. gonorrhoeae prevalence was highest
in jail inmates/STD clinic patients (3.5%), followed by hospi-
tal-associated patients (2.2%), family planning centers (1.5%),
and family practice/internal medicine practices (1.2%), and
lowest in OB/GYN practices (0.78%).
The subset of jail inmates had the overall highest rate of T.
vaginalis (22.3%) and C. trachomatis (10.9%) infections, and the
subset of inpatients had the highest overall rates of N. gonorrhoeae
infections (4.0%). Univariate and multivariate analyses (Table 2)
determined that T. vaginalis and N. gonorrhoeae infections were
significantly associated with jail inmates/STD clinic attendees,
while only T. vaginalis infections were significantly associated with
women treated in hospital settings.
The highest U.S. rates for T. vaginalis, C. trachomatis, and N.
TABLE 1 Prevalence of T. vaginalis, C. trachomatis, and N. gonorrhoeae infections by age, race, and collection site
Characteristic or prevalence categorya n
Prevalence (%)b










Overall prevalence (no. infected/total
no. of samples)
7,593 8.7 (663/7,593) 6.7 (508/7,588) 1.7 (129/7,579) 0.24 (18/7,577) 1.3 (97/7,588) 0.61 (46/7,577) 0.61 (46/7,579)
Mean age (yr) (SD) 29.82 (10.62) 23.4 (6.0) 24.0 (6.9) 22.00 (2.35) 23.41 (5.49) 21.89 (3.78) 23.15 (5.53)
Median age (yr) (minimum-maximum) 26.0 (18–82) 22.0 (18–65) 22.0 (18–53) 21.5 (18–26) 22 (18–46) 21 (18–37) 21.5 (18–50)
Age
18 and 20 907 8.5 14.4 3.3 0.2 2.1 1.3 0.9
20 and 30 3,975 8.3 8.0 2.0 0.4 1.7 0.8 0.9
30 and 40 1,667 7.9 2.5 0.8 0.0 0.4 0.1 0.2
40 1,044 11.8 1.7 0.5 0.0 0.3 0.0 0.1
Race
White 1,668 5.7 5.7 1.6 0.1 0.6 0.4 0.5
Black 1,385 20.2 12.1 4.0 0.7 3.6 1.7 1.7
Hispanic/Latino 718 5.0 5.9 0.7 0.0 0.6 0.0 0.1
All others/unknownc 3,822 6.6 5.3 1.1 0.2 0.9 0.5 0.3
Collection site
Family planning 784 5.4 10.4 1.5 0.0 1.4 0.5 0.1
Hospitald 493 16.6 7.3 2.2 1.0 3.0 1.0 1.6
Family practice, internal medicine 817 6.1 7.8 1.2 0.0 0.4 0.4 0.0
OB/GYN 2,059 7.3 4.4 0.8 0.2 0.9 0.3 0.3
Jail, STD clinic 1,304 16.4 10.5 3.5 0.5 2.5 1.3 1.5
Other/unknown 2,136 5.9 4.6 1.6 0.2 0.8 0.5 0.6
a SD, standard deviation.
b In the calculations of prevalence, the denominator may be less than the number shown for n due to missing or invalid assay data. Values are the prevalence unless otherwise
indicated in the stub entry for that row (i.e., mean and median age). Values given in parentheses are identified by the information in parentheses in the stub entry for that row.
c “Other” races include American Indian, Native Alaskan, Asian, and Native Hawaiian/Pacific Islander.
d Consists of patients seen in an emergency department and/or hospitalized.
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gonorrhoeae were found in the Southeast (14.4%, 7.9%, and 2.5%,
respectively), followed by the Southwest (9.5%, 7.8%, and 1.7%,
respectively) and the Midwest (9.5%, 6.6%, and 2.2%, respec-
tively). The Northeast had the lowest rates for all three STDs (T.
vaginalis, 4.3%; C. trachomatis, 4.8%; N. gonorrhoeae, 0.9%). Uni-
variate and multivariate analyses (Table 2) determined that the
Southwest, Southeast, and Midwest were significantly associated
with increased odds of T. vaginalis infections. The Southwest and
Southeast were significantly associated with increased odds for C.
trachomatis infections, and the Southeast and Midwest were sig-
nificantly associated with increased odds for N. gonorrhoeae infec-
tions. By univariate analysis only, C. trachomatis infections were
determined to be significantly associated with the Midwest and N.
gonorrhoeae infections were determined to be significantly associ-
ated with the Southwest.
Prevalence of T. vaginalis, C. trachomatis, and N. gonor-
rhoeae infections by specimen type. The prevalence of T. vagina-
lis, C. trachomatis, and N. gonorrhoeae infections by specimen type
is presented in Table 3. Since only one sample type per patient was
tested in this study, a direct comparison of detection rates by sam-
ple type was not possible. However, the overall prevalence rates for
C. trachomatis, N. gonorrhoeae, T. vaginalis, and coinfections were
equivalent for CVS and urine. The prevalence rates for C. tracho-
matis, N. gonorrhoeae, and T. vaginalis were slightly lower for en-
docervical swabs than for CVS and urine, but the rates for all
samples were equivalent for coinfections. PCyt specimens had the
lowest detection rates for C. trachomatis, N. gonorrhoeae, T. vagi-
nalis, and coinfections.
DISCUSSION
Prevalence of T. vaginalis is not well characterized primarily be-
cause T. vaginalis infections are not reportable to public health
officials and are generally not part of routine screening. In addi-
tion, published studies that measured T. vaginalis prevalence gen-
erally used relatively insensitive methods. This study is the first to
use the highly sensitive (95%) ATV to determine T. vaginalis
prevalence in a large number of U.S. women of all ages undergoing
screening or diagnostic testing for C. trachomatis/N. gonorrhoeae
infections. The use of remnant samples allowed the comparison of
T. vaginalis, C. trachomatis, and N. gonorrhoeae prevalences in
various patient populations, clinical settings, and different geo-
graphical regions (21 states). Consecutive enrollment of all sam-
ples meeting inclusion criteria prevented sample selection bias.
Our study had several limitations that need to be considered
when interpreting the data. The population is not nationally rep-
resentative of the U.S. population in general, and no Pacific
Northwest sites participated. Patient selection was biased (women
were screened for C. trachomatis/N. gonorrhoeae), and the reasons
for C. trachomatis/N. gonorrhoeae testing varied among age
groups. Younger age groups (18 to 30 years old) were tested as
part of routine screening (asymptomatic) or due to symptomatic
complaints and therefore constituted a significant portion of the
samples enrolled (4,882, versus 2,711 samples from women 30
years old). In contrast, women 50 years old were most likely
symptomatic, as routine C. trachomatis/N. gonorrhoeae screening
is not done in this age group. This study did not include sexually
active women 18 years old. Studies by Goyal et al. determined
FIG 1 Prevalence rates by age. TV, Trichomonas vaginalis; CT, Chlamydia trachomatis; GC, Neisseria gonorrhoeae. Prevalence rates for women of younger ages
(30 years) are biased toward an asymptomatic population per CDC screening guidelines. Higher prevalence rates in older women are biased toward a
symptomatic population.
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the T. vaginalis prevalence to be 9.9% in women 14 to 19 years old
who presented to the ED with complaints suggestive of an STI
(12). Another study by Huppert et al. found that the T. vaginalis
prevalence was 18.5% in women 14 to 21 years old (18). Due to the
use of deidentified, discarded clinical samples, patient clinical sta-
tus (asymptomatic or symptomatic), history of sexual partners,
and history of STIs could not be obtained, thereby limiting the
interpretation of the data. Therefore, the age of the patient con-
tributes to the bias in STI prevalence noted in this study, and
overall T. vaginalis rates may be underestimated by exclusion of
certain populations. Finally, this study was not intended to com-
pare the performances of the assays in the various specimen types,
as multiple specimen types from each patient were not tested.
However, overall, the detection rates for C. trachomatis, N. gonor-
rhoeae, and T. vaginalis were highly comparable in CVS and urine
specimens and only slightly lower for ES. These specimen types
accounted for 86.7% of the types tested, and comparable C. tra-
chomatis, N. gonorrhoeae, and T. vaginalis detection rates suggest
that no major disparities in assay performance by specimen type
biased the overall results. As expected, the lowest detection rates
for C. trachomatis, N. gonorrhoeae, and T. vaginalis were for PCyt
specimens, as PCyt is used primarily for cervical cancer screening
and STI testing is generally performed as adjunctive routine
screening.
Despite these limitations, the following observations are of
clinical significance. Strengths of the study included a substantial
sample size, the availability of C. trachomatis/N. gonorrhoeae in-
fection status, and the use of highly sensitive NAATs for T. vagi-
nalis and C. trachomatis/N. gonorrhoeae testing from the same
sample.
T. vaginalis prevalence was 8.7% in the overall study popula-
tion. This value is higher than the 3.2% value reported in the 2001
to 2004 NHANES, the most recent study reporting T. vaginalis
prevalence in the general U.S. female population (1). The differ-
ence in prevalence between this study and NHANES may be at-
tributed to various factors. First, it may be due to an increase in T.
vaginalis prevalence in the last 6 to 9 years (NHANES utilized data
from 2001 to 2004). Second, the higher sensitivity of ATV com-
pared to that of the PCR used in NHANES allows the detection of
TABLE 2 Univariate and multivariate analyses of risk factors associated with T. vaginalis, C. trachomatis, and N. gonorrhoeae infections
Risk factor
Indicated values for each infectiona
T. vaginalis C. trachomatis N. gonorrhoeae
Prevalence


















18 and 20 8.49 1 1 14.35 1 1 3.31 1 1
20 and 30 8.33 0.98 (0.76–1.27) 1.03 (0.79–1.36) 8.03 0.52 (0.42–0.65) 0.53 (0.42–0.66) 2.04 0.61 (0.40–0.93) 0.66 (0.43–1.02)
30 and 40 7.92 0.93 (0.69–1.24) 1.03 (0.76–1.40) 2.52 0.15 (0.11–0.22) 0.17 (0.11–0.24) 0.78 0.23 (0.12–0.44) 0.27 (0.14–0.52)
40 11.78 1.44 (1.07–1.94) 1.51 (1.10–2.07) 1.63 0.10 (0.06–0.17) 0.09 (0.06–0.16) 0.48 0.14 (0.05–0.37) 0.14 (0.06–0.37)
Race
White 5.70 1 1 5.70 1 1 1.56 1 1
Black 20.22 4.15 (3.25–5.31) 4.04 (3.12–5.22) 12.08 2.34 (1.80–3.06) 2.63 (1.99–3.49) 3.98 2.67 (1.66–4.29) 2.66 (1.61–4.41)
Hispanic/Latino 5.01 0.86 (0.58–1.27) 0.88 (0.58–1.32) 5.85 1.18 (0.80–1.72) 1.29 (0.87–1.94) 0.70 0.49 (0.19–1.29) 0.60 (0.22–1.64)
All others/unknown 6.59 1.15 (0.90–1.46) 0.92 (0.69–1.23) 5.34 1.07 (0.83–1.38) 1.54 (1.15–2.06) 1.13 0.80 (0.49–1.31) 0.71 (0.40–1.27)
Clinic type
Family planning 5.36 1 1 10.36 1 1 1.54 1 1
Hospital 16.63 3.53 (2.38–5.21) 3.50 (2.30–5.32) 7.30 0.68 (0.45–1.03) 0.65 (0.42–1.00) 2.24 1.47 (0.64–3.35) 2.00 (0.83–4.82)
Family practice, internal
medicine
6.12 1.15 (0.76–1.76) 1.27 (0.80–2.01) 7.83 0.74 (0.52–1.04) 0.87 (0.60–1.28) 1.23 0.80 (0.34–1.87) 1.62 (0.65–4.02)
OB/GYN 7.29 1.39 (0.98–1.98) 1.33 (0.90–1.98) 4.42 0.40 (0.29–0.55) 0.40 (0.28–0.57) 0.78 0.50 (0.24–1.07) 0.73 (0.32–1.70)
Jail, STD clinic 16.41 3.47 (2.46–4.89) 2.59 (1.77–3.80) 10.52 1.02 (0.76–1.36) 0.91 (0.65–1.26) 3.45 2.29 (1.21–4.36) 2.73 (1.32–5.65)
Other/unknown 5.85 1.10 (0.77–1.57) 1.67 (1.12–2.49) 4.64 0.42 (0.31–0.57) 0.47 (0.33–0.66) 1.64 1.07 (0.55–2.07) 2.36 (1.12–4.95)
Region
Northeast 4.30 1 1 4.78 1 1 0.92 1 1
Southwest 9.51 2.35 (1.83–3.01) 1.88 (1.40–2.50) 7.76 1.82 (1.42–2.34) 1.51 (1.13–2.03) 1.68 1.94 (1.13–3.34) 1.64 (0.88–3.06)
Southeast 14.44 3.78 (2.87–4.98) 6.32 (4.62–8.63) 7.88 1.83 (1.34–2.50) 2.26 (1.60–3.19) 2.49 2.90 (1.59–5.31) 6.77 (3.45–13.29)
Midwest 9.48 2.35 (1.80–3.05) 2.00 (1.50–2.65) 6.64 1.39 (1.06–1.83) 1.16 (0.86–1.56) 2.20 2.38 (1.37–4.13) 2.33 (1.29–4.22)
a Multivariate analysis odds ratio (OR) estimates were adjusted for age, race, clinic type, and region. CI, confidence interval.
b Five observations were deleted due to missing values for the response or explanatory variables.
c Fourteen observations were deleted due to missing values for the response or explanatory variables.
FIG 2 Prevalence rates by racial/ethnic group. TV, Trichomonas vaginalis; CT,
Chlamydia trachomatis; GC, Neisseria gonorrhoeae. The other/unknown group
includes American Indians, Alaskan Natives, Native Hawaiians/Pacific Island-
ers, and Asians.
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a higher number of cases and therefore may have yielded a higher
prevalence. Third, and most important, the populations analyzed
in NHANES and the present study differed. The NHANES popu-
lation consisted of noninstitutionalized civilians selected at ran-
dom that represent the entire U.S. population because the data set
was weighted based on U.S. Census data and was generally a low-
risk population. In contrast, our study population was inherently
at higher risk for STIs since the subjects were undergoing testing
for C. trachomatis/N. gonorrhoeae. It is unknown what percentage
of the patients were asymptomatic for C. trachomatis/N. gonor-
rhoeae and being screened according to current guidelines (5, 35)
or were symptomatic for C. trachomatis/N. gonorrhoeae and being
tested for diagnosis of C. trachomatis/N. gonorrhoeae. Regardless
of the symptomatic status, this population can be considered po-
tentially high risk for STIs since the CDC and other guidelines
recommend annual C. trachomatis/N. gonorrhoeae screening of
sexually active women under 26 years or older women with risk
factors, such as new sexual partners. In addition, our population
was 18.2% black (which is larger than the national average of
12.8%) (30), a population known to have high T. vaginalis preva-
lence (13% to 14%) (1, 29).
Like NHANES, we found that T. vaginalis prevalence was
higher than that for C. trachomatis and N. gonorrhoeae combined,
even though C. trachomatis and N. gonorrhoeae prevalence in our
population was higher than that reported in NHANES (2.2% for
C. trachomatis and 0.24% for N. gonorrhoeae) (9). A recent prev-
alence study, in which home-collected mailed vaginal swabs were
tested by ATV, reported a 10% prevalence of T. vaginalis in
women (11). Unlike our study, that report did not find that age
was significantly associated with T. vaginalis positivity. Like the
present study, however, black race was highly associated with T.
vaginalis infection (adjusted OR, 2.69; prevalence, 13.2%).
An analysis of T. vaginalis prevalence by age group revealed
that T. vaginalis infection affects women of all ages and that T.
vaginalis prevalence is highest in women 40 years old and lowest
in women 40 years old. These findings are in agreement with
NHANES (1, 29) and other studies (3, 10, 23, 27). This age distri-
bution contrasts with that of C. trachomatis and N. gonorrhoeae,
whose prevalence was highest in women 30 years old and lowest
in women 40 years old (9). T. vaginalis prevalence remained
higher than that of C. trachomatis and N. gonorrhoeae for all age
groups except the youngest women (18 to 19 years), for whom C.
trachomatis prevalence was highest. This trend agrees with a pre-
vious study that reported C. trachomatis, T. vaginalis, and N. gon-
orrhoeae prevalence rates of 10.1%, 6.0%, and 4.1%, respectively,
FIG 4 Prevalence rates by geographical region. TV, Trichomonas vaginalis;
CT, Chlamydia trachomatis; GC, Neisseria gonorrhoeae.
FIG 3 Prevalence rates by testing site. TV, Trichomonas vaginalis; CT, Chlamydia trachomatis; GC, Neisseria gonorrhoeae; Int Med, internal medicine; STD,
sexually transmitted disease.
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in women 14 to 17 years old (32) and with results from another
study that showed prevalence rates of 11%, 6.3%, and 0%, respec-
tively, in women 13 to 21 years old (16). Rates of T. vaginalis, C.
trachomatis, and N. gonorrhoeae coinfection were low (1.3%) in
the whole population. Other studies reported coinfection rates in
high-risk populations or reported C. trachomatis and N. gonor-
rhoeae prevalence in T. vaginalis-positive women (1, 24). T. vagi-
nalis/C. trachomatis and T. vaginalis/N. gonorrhoeae coinfections
were more common in women 30 years old, probably because C.
trachomatis and N. gonorrhoeae infections are more prevalent in
this age group.
An analysis of STI prevalence by ethnicity showed large dispar-
ities. T. vaginalis, C. trachomatis, and N. gonorrhoeae prevalences
were highest in black populations, a trend documented in the U.S.
population for T. vaginalis as well as for C. trachomatis and N.
gonorrhoeae (1, 9, 11, 15, 17, 29). NHANES found the highest T.
vaginalis rates in non-Hispanic black women (13.3%), and within
this group, T. vaginalis rates increased from 8.3% (14 to 19 years)
to almost 20% (40 to 49 years) (1). A significant association be-
tween black race and T. vaginalis prevalence was reported for
high-risk adolescent females (16). Although other ethnic groups
(American Indians/Alaskan Natives and Native Hawaiians/Pacific
Islanders) had high T. vaginalis prevalence rates, due to low sub-
ject numbers, we cannot conclude that this prevalence is truly
representative in these ethnic groups.
We found that T. vaginalis prevalence and, in some cases, C.
trachomatis and N. gonorrhoeae prevalence were highest in women
attending STD clinics, testing in a hospital setting, and incarcer-
ated in jails. High T. vaginalis prevalence (32%) has been observed
among women incarcerated in San Francisco county jail (10).
Similar findings relating to C. trachomatis and N. gonorrhoeae in-
fections were reported for black adolescents 18 to 19 years old who
were incarcerated in adult correction facilities (19). Although
women attending STD clinics are expected to have high T. vagi-
nalis, C. trachomatis, and N. gonorrhoeae rates due to high-risk
behavior and/or symptomatic status, providers should be aware of
the high T. vaginalis rates in the hospital setting. Patients who are
presenting with symptomatic vaginal complaints and using the
ED as the primary source of health care may contribute to this
high rate and will require further investigation. Interestingly, cor-
responding C. trachomatis and N. gonorrhoeae rates were not par-
ticularly high in this setting. This lower prevalence in OB/GYN,
family practice/internal medicine, and family planning clinics
might be expected since many of these women were probably
being routinely screened according to C. trachomatis/N. gonor-
rhoeae testing guidelines and were 26 years old and/or pregnant.
Interestingly, women in family planning and family practice
groups had higher rates of C. trachomatis than T. vaginalis.
In summary, the availability of the FDA-cleared ATV, which
can be run on the same fully automated system and with the same
samples as AC2, provides a unique opportunity to screen women
at risk for Trichomonas vaginalis, Chlamydia trachomatis, and
Neisseria gonorrhoeae infections. High T. vaginalis prevalence in
all age groups suggests that all women that are considered at high
risk for STIs (multiple or new partners, non-barrier contracep-
tion, etc.), including women 40 years old, should be screened for
T. vaginalis even if they are not being tested for C. trachomatis/N.
gonorrhoeae. T. vaginalis screening can be performed when these
women appear for routine adjunct human papillomavirus (HPV)/
cytology screening since all testing can be done using the same
PCyt sample or a separate swab sample. The high prevalence of T.
vaginalis infection, particularly in asymptomatic women, empha-
sizes the need for T. vaginalis to be made a reportable disease by
the CDC. Further studies using ATV are needed to estimate the
true prevalence of T. vaginalis in adolescent females younger than
18 years of age.
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